Summary
- Inozyme Pharma has filed to raise $86 million in a U.S. IPO.
- The firm is developing treatments for abnormal calcification diseases.
- INZY has produced promising preclinical testing results but the firm is still at a very early stage of development, so the IPO may be more suited to institutional investors.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Inozyme Pharma (INZY) has filed to raise $86.25 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is developing treatment candidates for rare diseases of abnormal mineralization in various parts of the human body.
INZY has produced intriguing preclinical results for its lead programs.
I’ll provide a final opinion when we learn more details about the IPO from management.
Company & Technology
Boston, Massachusetts-based Inozyme was founded to advance treatments for defective gene expression of the ENPP1 and ABCC6 genes that produce increased arterial calcification and other deleterious calcium deposition effects throughout the body in the vasculature, soft tissue and skeleton.
Management is headed by president and Chief Executive Officer Mr. Axel Bolte, who has been with the firm since 2015 and was previously managing member of a healthcare advisory firm and venture partner at HBM Partners, AG.
Below is a brief overview video of a coronary calcification:
